Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 10/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | ARAF | P10398 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883316 | 0.87 | MAPK14 (0.44) | EGFRCYP3A4BRAFJAK3KCNH2 | |
| SCHEMBL1876011 | 0.84 | MAPK14 (0.40) | CYP3A4MAPK14 | |
| SCHEMBL1875418 | 0.83 | MAPK14 (0.52) | MAPK10MAPK14 | |
| SCHEMBL1874241 | 0.79 | POLB (0.40) | CYP3A4MAPK10MAPK14 | |
| SCHEMBL1872450 | 0.74 | EGFR (0.54) | EGFRCYP3A4BRAFJAK3KCNH2 | |
| SCHEMBL1881585 | 0.72 | MAPK14 (0.56) | MAPK10MAPK14 | |
| SCHEMBL1875148 | 0.72 | MAPK14 (0.51) | MAPK10MAPK14 | |
| SCHEMBL1874168 | 0.71 | MAPK14 (0.45) | CYP3A4MAPK10MAPK14 | |
| SCHEMBL1877120 | 0.70 | MAPK14 (0.52) | IGF1RBACE1MAPK14 | |
| SCHEMBL1874664 | 0.68 | MAPK14 (0.47) | CYP3A4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1832584-B1 | PYRIMIDINYLISOXAZOLE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-7939536-B2 | 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20080114003-A1 | Pyrimidinylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1832584-A1 | PYRIMIDINYLISOXAZOL DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114003-A1 | Pyrimidinylisoxazole Derivatives | MAPK3, MAPK7, MAP3K7 | EGFR 1375/4885CYP3A4 1031/4885BRAF 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.